Lancashire and South Cumbria
Formulary
Home
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Cobicistat
found
20 matches
Formulary items
6 matches
Open monograph to display formulary status
BNF Category
Atazanavir sulfate and
Cobicistat
(Evotaz
®
)
Infections - HIV infection - 05.03.01
Cobicistat
Infections - HIV infection - 05.03.01
Darunavir with
Cobicistat
(Rezolsta
®
)
Infections - Other antiretrovirals - 05.03.01
Darunavir with
Cobicistat
, Emtricitabine and Tenofovir alafenamide
(Symtuza
®
)
Infections - Other antiretrovirals - 05.03.01
Elvitegravir with
Cobicistat
, emtricitabine and tenofovir disoproxil
(Stribild
®
)
Infections - Nucleoside reverse transcriptase inhibitors - 05.03.01
Tenofovir alafenamide, elvitegravir,
Cobicistat
& emtricitabine
(Genvoya
®
)
Infections - HIV infection - 05.03.01
Links
Link to Drug Section
Link to document
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (05.03.01)
